{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:16:43Z","timestamp":1792451803463,"version":"4.5.0"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jare.2026.07.035","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:34:01Z","timestamp":1784676841000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tumor-specific mechanisms and therapeutic strategies for overcoming immunotherapy resistance in advanced urological tumors"],"prefix":"10.1016","author":[{"given":"Pinying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9187-3461","authenticated-orcid":false,"given":"Shan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8677-8475","authenticated-orcid":false,"given":"Gautam","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengnan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jare.2026.07.035_b0005","doi-asserted-by":"crossref","unstructured":"Filho AM, Briganti A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol; 2025.","DOI":"10.1016\/j.eururo.2025.12.011"},{"key":"10.1016\/j.jare.2026.07.035_b0010","doi-asserted-by":"crossref","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer Stat 2024. 2024; 74(1):12\u201349.","DOI":"10.3322\/caac.21820"},{"issue":"1","key":"10.1016\/j.jare.2026.07.035_b0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41571-023-00826-2","article-title":"Progress in systemic therapy for advanced-stage urothelial carcinoma","volume":"21","author":"Nadal","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.jare.2026.07.035_b0020","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2174\/0115680096278251240108152600","article-title":"Research progress of PD 1\/PD L1 inhibitors in the treatment of urological tumors","volume":"24","author":"Han","year":"2024","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.jare.2026.07.035_b0025","article-title":"Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial","volume":"6(2):253-258","author":"Marabelle","year":"2025","journal-title":"Nature Cancer"},{"issue":"6382","key":"10.1016\/j.jare.2026.07.035_b0030","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jare.2026.07.035_b0035","doi-asserted-by":"crossref","first-page":"416","DOI":"10.20517\/cdr.2023.02","article-title":"Mechanisms and clinical implications in renal carcinoma resistance: narrative review of immune checkpoint inhibitors","volume":"6","author":"Samnani","year":"2023","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.jare.2026.07.035_b0040","article-title":"Review of recent molecular pathology of bladder urothelial carcinoma","volume":"16(1):424","author":"Su","year":"2025","journal-title":"Discov Oncol"},{"issue":"1","key":"10.1016\/j.jare.2026.07.035_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CU9.0000000000000312","article-title":"Molecular mechanisms and classification of castration-resistant prostate cancer: Insights into androgen receptor, cancer stem cells, and neuroendocrine features","volume":"20","author":"Shao","year":"2026","journal-title":"Curr Urol"},{"issue":"1","key":"10.1016\/j.jare.2026.07.035_b0050","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/21541264.2024.2417475","article-title":"Hypoxia-inducible transcription factors: architects of tumorigenesis and targets for anticancer drug discovery","volume":"16","author":"McDermott","year":"2025","journal-title":"Transcription"},{"issue":"9","key":"10.1016\/j.jare.2026.07.035_b0055","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.tem.2024.12.003","article-title":"Tumor-intrinsic regulators of the immune-cold microenvironment of prostate cancer","volume":"36","author":"Brea","year":"2025","journal-title":"Trends Endocrinol Metabol"},{"issue":"5","key":"10.1016\/j.jare.2026.07.035_b0060","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","article-title":"Epidemiology of renal cell carcinoma: 2022 update","volume":"82","author":"Bukavina","year":"2022","journal-title":"Eur Urol"},{"issue":"10189","key":"10.1016\/j.jare.2026.07.035_b0065","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.jare.2026.07.035_b0070","first-page":"00073","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial","volume":"S0923\u20137534","author":"Choueiri","year":"2026","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.jare.2026.07.035_b0075","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1038\/s41591-025-03867-5","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial","volume":"31","author":"Rini","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jare.2026.07.035_b0080","article-title":"PD-1 blockade plus tyrosine kinase inhibitor remodels the tumor microenvironment in advanced renal cell carcinoma","author":"Gu","year":"2026","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.jare.2026.07.035_b0085","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1158\/1078-0432.CCR-23-1892","article-title":"Management of renal cell carcinoma: promising biomarkers and the challenges to reach the clinic","volume":"30","author":"Lyskj\u00e6r","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.jare.2026.07.035_b0090","doi-asserted-by":"crossref","first-page":"E235","DOI":"10.1503\/cmaj.230356","article-title":"Advances in the management of renal cell carcinoma","volume":"196","author":"Cardenas","year":"2024","journal-title":"CMAJ"},{"issue":"14","key":"10.1016\/j.jare.2026.07.035_b0095","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jare.2026.07.035_b0100","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"10122","key":"10.1016\/j.jare.2026.07.035_b0105","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"issue":"7528","key":"10.1016\/j.jare.2026.07.035_b0110","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"Teng S-l et al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"issue":"10064","key":"10.1016\/j.jare.2026.07.035_b0115","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jare.2026.07.035_b0120","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s10147-025-02950-8","article-title":"Pan-asian subgroup analysis of EV-302\/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma","volume":"31","author":"Kikuchi","year":"2026","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jare.2026.07.035_b0125","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2023.03.030","article-title":"Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup analyses from the JAVELIN Bladder 100 phase 3 Trial","volume":"84","author":"Grivas","year":"2023","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.jare.2026.07.035_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102356","article-title":"Response and Survival with Immune Checkpoint Inhibitor in patients with Advanced Urothelial Carcinoma and Histology Subtypes","volume":"23","author":"Bakaloudi","year":"2025","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.jare.2026.07.035_b0135","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"6280","key":"10.1016\/j.jare.2026.07.035_b0140","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jare.2026.07.035_b0145","first-page":"243","article-title":"Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs","volume":"15","author":"Ferretti","year":"2023","journal-title":"Res Rep Urol"},{"issue":"16","key":"10.1016\/j.jare.2026.07.035_b0150","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate Cancer: a Review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"J Am Med Assoc"},{"issue":"20","key":"10.1016\/j.jare.2026.07.035_b0155","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO-25-00007","article-title":"Systemic Therapy in patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update","volume":"43","author":"Garje","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jare.2026.07.035_b0160","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","article-title":"Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial","volume":"28","author":"Powles","year":"2022","journal-title":"Nat Med"},{"issue":"14","key":"10.1016\/j.jare.2026.07.035_b0165","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO-24-01283","article-title":"Pembrolizumab Plus Docetaxel Versus Docetaxel for previously Treated Metastatic Castration-Resistant Prostate Cancer: the Randomized, Double-blind, phase III KEYNOTE-921 Trial","volume":"43","author":"Petrylak","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jare.2026.07.035_b0170","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label phase II KEYNOTE-199 Study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jare.2026.07.035_b0175","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.euo.2023.10.008","article-title":"Pembrolizumab and Enzalutamide in patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the phase 1b\/2 KEYNOTE-365 Study","volume":"7","author":"Yu","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.jare.2026.07.035_b0180","article-title":"Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion","volume":"11(1):2","author":"Wu","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jare.2026.07.035_b0185","doi-asserted-by":"crossref","unstructured":"Kwon W-A, Joung JY: Immunotherapy in Prostate Cancer: From a \u201cCold\u201d Tumor to a \u201cHot\u201d Prospect. Cancers 2025, 17(7):1064.","DOI":"10.3390\/cancers17071064"},{"key":"10.1016\/j.jare.2026.07.035_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100907","article-title":"Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade","volume":"66","author":"Pang","year":"2023","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.jare.2026.07.035_b0195","article-title":"Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer: a novel molecular subtyping strategy and immunotherapeutic prediction model","volume":"22(1):365","author":"Zheng","year":"2024","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.jare.2026.07.035_b0200","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41577-025-01208-8","article-title":"Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development","volume":"26","author":"Huber","year":"2026","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.jare.2026.07.035_b0205","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s13258-025-01710-2","article-title":"Tumor microenvironment-driven drug resistance in urologic cancers: mechanisms and therapeutic targets","volume":"48","author":"Yang","year":"2026","journal-title":"Genes Genomics"},{"issue":"5","key":"10.1016\/j.jare.2026.07.035_b0210","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrc.2017.6","article-title":"Pre-metastatic niches: organ-specific homes for metastases","volume":"17","author":"Peinado","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.jare.2026.07.035_b0215","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eururo.2023.05.023","article-title":"Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer","volume":"85","author":"Feng","year":"2024","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.jare.2026.07.035_b0220","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jare.2026.07.035_b0225","article-title":"Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF\/FGFR signaling in tumor microenvironment","volume":"22(1):60","author":"Ruan","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jare.2026.07.035_b0230","article-title":"MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPC","volume":"22(1):145","author":"Wang","year":"2024","journal-title":"J Nanobiotechnology"},{"issue":"12","key":"10.1016\/j.jare.2026.07.035_b0235","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.jare.2026.07.035_b0240","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","article-title":"Identifying and Targeting Human Tumor Antigens for T Cell-based Immunotherapy of Solid Tumors","volume":"38","author":"Leko","year":"2020","journal-title":"Cancer Cell"},{"issue":"6230","key":"10.1016\/j.jare.2026.07.035_b0245","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jare.2026.07.035_b0250","doi-asserted-by":"crossref","unstructured":"Fernandez EM, Eng K, Beg S, Beltran H, Faltas BM, Mosquera JM, Nanus DM, Pisapia DJ, Rao RA, Robinson BD et al: Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution. JCO precision oncology 2019, 3.","DOI":"10.1200\/PO.18.00400"},{"issue":"4","key":"10.1016\/j.jare.2026.07.035_b0255","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/1078-0432.CCR-15-1678","article-title":"Microsatellite Instability as a Biomarker for PD-1 Blockade","volume":"22","author":"Dudley","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.jare.2026.07.035_b0260","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-Repair Gene Mutations in men with Metastatic Prostate Cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2026.07.035_b0265","doi-asserted-by":"crossref","first-page":"15180","DOI":"10.1038\/ncomms15180","article-title":"A molecular portrait of microsatellite instability across multiple cancers","volume":"8","author":"Cortes-Ciriano","year":"2017","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.jare.2026.07.035_b0270","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071760","article-title":"MHC Class I Downregulation in Cancer: underlying Mechanisms and potential Targets for Cancer Immunotherapy","volume":"12","author":"Cornel","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jare.2026.07.035_b0275","article-title":"HIF2\u03b1 drives ccRCC metastasis through transcriptional activation of methylation-controlled J protein and enhanced prolegumain secretion","volume":"16(1):93","author":"Shen","year":"2025","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1016\/j.jare.2026.07.035_b0280","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1158\/2159-8290.CD-24-0559","article-title":"Androgen Receptor Inhibition increases MHC Class I Expression and Improves Immune Response in Prostate Cancer","volume":"15","author":"Chesner","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jare.2026.07.035_b0285","article-title":"Epigenetic modifications in bladder cancer: crosstalk between DNA methylation and miRNAs","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jare.2026.07.035_b0290","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF03401948","article-title":"The transporter associated with antigen processing (TAP): structural integrity, expression, function, and its clinical relevance","volume":"7","author":"Ritz","year":"2001","journal-title":"Mol Med"},{"key":"10.1016\/j.jare.2026.07.035_b0295","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.semcancer.2020.07.001","article-title":"News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors","volume":"79","author":"Melaiu","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"12","key":"10.1016\/j.jare.2026.07.035_b0300","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jare.2026.07.035_b0305","article-title":"Chen C-y et al: HIF-1\u03b1 and HIF-2\u03b1 differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice","volume":"11(1):4111","author":"Hoefflin","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jare.2026.07.035_b0310","doi-asserted-by":"crossref","first-page":"234","DOI":"10.18632\/oncotarget.2703","article-title":"PD-L1 is highly expressed in Enzalutamide resistant prostate cancer","volume":"6","author":"Bishop","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jare.2026.07.035_b0315","article-title":"Prognostic significance and immunotherapeutic implications of CSF1R in renal cell carcinoma","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jare.2026.07.035_b0320","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-Associated Macrophages: from Mechanisms to Therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.jare.2026.07.035_b0325","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.jare.2026.07.035_b0330","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41391-024-00825-z","article-title":"Targeting the tumor microenvironment, a new therapeutic approach for prostate cancer","volume":"28","author":"Fang","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.jare.2026.07.035_b0335","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1387975","article-title":"Regulation of Treg cells by cytokine signaling and co-stimulatory molecules","volume":"15","author":"Zong","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jare.2026.07.035_b0340","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.3389\/fimmu.2018.02499","article-title":"Reactive Oxygen Species as regulators of MDSC-Mediated Immune suppression","volume":"9","author":"Ohl","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jare.2026.07.035_b0345","article-title":"Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments","volume":"10(1):268","author":"Xu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jare.2026.07.035_b0350","article-title":"TGF-\u03b2 inhibits the activation and functions of NK cells by repressing the mTOR pathway","volume":"9(415):ra19","author":"Viel","year":"2016","journal-title":"Sci Signal"},{"key":"10.1016\/j.jare.2026.07.035_b0355","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ijbiomac.2022.02.094","article-title":"Transforming growth factor-beta (TGF-\u03b2) in prostate cancer: a dual function mediator?","volume":"206","author":"Mirzaei","year":"2022","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.jare.2026.07.035_b0360","doi-asserted-by":"crossref","unstructured":"Maiorano BA, De Giorgi U, Ciardiello D, Schinzari G, Cisternino A, Tortora G, Maiello E: Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day. Biomedicines 2022, 10(2):411.","DOI":"10.3390\/biomedicines10020411"},{"issue":"3","key":"10.1016\/j.jare.2026.07.035_b0365","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.it.2012.10.001","article-title":"Indoleamine 2,3 dioxygenase and metabolic control of immune responses","volume":"34","author":"Munn","year":"2013","journal-title":"Trends Immunol"},{"issue":"6230","key":"10.1016\/j.jare.2026.07.035_b0370","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jare.2026.07.035_b0375","doi-asserted-by":"crossref","unstructured":"Lai J, Chen Z, Wu W: An integrative bioinformatics approach unveils fibrosis-driven prognostic signature and immunotherapeutic potential in kidney renal clear cell carcinoma. Toxicology and applied pharmacology 2025, 504:117533.","DOI":"10.1016\/j.taap.2025.117533"},{"issue":"5","key":"10.1016\/j.jare.2026.07.035_b0380","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.hoc.2023.04.011","article-title":"von-Hippel Lindau and Hypoxia-Inducible factor at the Center of Renal Cell Carcinoma Biology","volume":"37","author":"Shirole","year":"2023","journal-title":"Hematol Oncol Clin N Am"},{"issue":"10","key":"10.1016\/j.jare.2026.07.035_b0385","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41585-019-0226-y","article-title":"The multifaceted immune regulation of bladder cancer","volume":"16","author":"Schneider","year":"2019","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.jare.2026.07.035_b0390","doi-asserted-by":"crossref","unstructured":"Doshi GK, Osterland AJ, Shi P, Yim A, Del Tejo V, Guttenplan SB, Eiffert S, Yin X, Rosenblatt L, Conkling PR: Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States. JCO clinical cancer informatics 2024, 8:e2400132.","DOI":"10.1200\/CCI.24.00132"},{"key":"10.1016\/j.jare.2026.07.035_b0395","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.coi.2020.05.008","article-title":"Polymorphisms of HLA-B: influences on assembly and immunity","volume":"64","author":"Olson","year":"2020","journal-title":"Curr Opin Immunol"},{"issue":"9","key":"10.1016\/j.jare.2026.07.035_b0400","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/s41423-025-01326-2","article-title":"Lau HC-H, Yu J: the gut microbiota in cancer immunity and immunotherapy","volume":"22","author":"Xie","year":"2025","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"10.1016\/j.jare.2026.07.035_b0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.33696\/cancerimmunol.6.078","article-title":"The Role of Tumor and Host Microbiome on Immunotherapy Response in Urologic Cancers","volume":"6","author":"Pfail","year":"2024","journal-title":"Journal of cancer immunology"},{"key":"10.1016\/j.jare.2026.07.035_b0410","doi-asserted-by":"crossref","unstructured":"D'Andrea VD, Magnani CJ, Ernandez J, Bellmunt J, Mossanen M, Clinton TN, Carvalho FLF, Mouw KW: Impact of DNA Repair Deficiency in the Evolving Treatment Landscape of Bladder Cancer. Current urology reports 2024, 26(1):12.","DOI":"10.1007\/s11934-024-01242-4"},{"issue":"2","key":"10.1016\/j.jare.2026.07.035_b0415","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41568-024-00772-w","article-title":"Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities","volume":"25","author":"Dotto","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jare.2026.07.035_b0420","article-title":"Developing angiogenesis-related prognostic biomarkers and therapeutic strategies in bladder cancer using deep learning and machine learning","volume":"15(1):25534","author":"Li","year":"2025","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.jare.2026.07.035_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.acuroe.2025.501719","article-title":"Biological and therapeutic implications of FGFR alterations in urothelial cancer: a systematic review from non-muscle-invasive to metastatic disease","volume":"49","author":"Pichler","year":"2025","journal-title":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"},{"key":"10.1016\/j.jare.2026.07.035_b0430","doi-asserted-by":"crossref","unstructured":"Zhang C, Zhang C, Wang H: Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions. Cancer Letters 2023, 562:216182.","DOI":"10.1016\/j.canlet.2023.216182"},{"key":"10.1016\/j.jare.2026.07.035_b0435","article-title":"EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer","volume":"9(1):3503","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jare.2026.07.035_b0440","doi-asserted-by":"crossref","unstructured":"Evans ST, Jani Y, Jansen CS, Yildirim A, Kalemoglu E, Bilen MA: Understanding and overcoming resistance to immunotherapy in genitourinary cancers. Cancer biology & therapy 2024, 25(1):2342599.","DOI":"10.1080\/15384047.2024.2342599"},{"issue":"6","key":"10.1016\/j.jare.2026.07.035_b0445","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"issue":"12","key":"10.1016\/j.jare.2026.07.035_b0450","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat Immunol"},{"issue":"3","key":"10.1016\/j.jare.2026.07.035_b0455","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/leu.2016.328","article-title":"PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia","volume":"31","author":"Goltz","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jare.2026.07.035_b0460","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2017.10.022","article-title":"Epigenetic Therapy Ties MYC Depletion to reversing Immune Evasion and Treating Lung Cancer","volume":"171","author":"Topper","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jare.2026.07.035_b0465","article-title":"Fu Y-X et al: PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade","volume":"11(1):4835","author":"Peng","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jare.2026.07.035_b0470","article-title":"Programmed death receptor (PD-)1\/PD-ligand (L)1 in urological cancers : the \u201call-around warrior\u201d in immunotherapy","volume":"23(1):183","author":"Liu","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jare.2026.07.035_b0475","article-title":"Single-cell and spatial transcriptomics reveal SPP1-CD44 signaling drives primary resistance to immune checkpoint inhibitors in RCC","volume":"22(1):1157","author":"Zhang","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.jare.2026.07.035_b0480","article-title":"Clonal diversity shapes the tumour microenvironment leading to distinct immunotherapy responses in metastatic urothelial carcinoma","volume":"16(1):7995","author":"Kamatani","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.jare.2026.07.035_b0485","article-title":"Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling","volume":"10(1):2977","author":"Robinson","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jare.2026.07.035_b0490","article-title":"Shohdy KS et al: the evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis","volume":"15(1):2009","author":"Ohara","year":"2024","journal-title":"Nat Commun"},{"issue":"8048","key":"10.1016\/j.jare.2026.07.035_b0495","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","article-title":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer","volume":"637","author":"Lyu","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jare.2026.07.035_b0500","doi-asserted-by":"crossref","unstructured":"Kalogirou C, Krebs M, Kunz AS, Hahn O, K\u00fcbler H, Schwinger M, Hartmann A, Schmieder A, Eckstein M: Spatial transcriptomic profiling of metastatic renal cell carcinoma identifies chemokine-driven macrophage and CD8+ T-cell interactions predictive of immunotherapy response. Journal for ImmunoTherapy of Cancer 2025, 13(10):e012991.","DOI":"10.1136\/jitc-2025-012991"},{"key":"10.1016\/j.jare.2026.07.035_b0505","article-title":"Metabolic heterogeneity in clear cell renal cell carcinoma revealed by single-cell RNA sequencing and spatial transcriptomics","volume":"22(1):210","author":"Yang","year":"2024","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.jare.2026.07.035_b0510","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010183","article-title":"Spatial and single-cell transcriptomics reveal cellular heterogeneity and a novel cancer-promoting Treg cell subset in human clear-cell renal cell carcinoma","volume":"13","author":"Song","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.jare.2026.07.035_b0515","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1007\/s00262-022-03204-6","article-title":"Clinical and molecular correlates of response to immune checkpoint blockade in urothelial carcinoma with liver metastasis","volume":"71","author":"Yoshida","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jare.2026.07.035_b0520","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1522582","article-title":"Spatially-resolved analyses of muscle invasive bladder cancer microenvironment unveil a distinct fibroblast cluster associated with prognosis","volume":"15","author":"Feng","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jare.2026.07.035_b0525","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2147\/CMAR.S495169","article-title":"Prostate Cancer Bone Metastasis: Molecular Mechanisms of Tumor and Bone Microenvironment","volume":"17","author":"Jiang","year":"2025","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.jare.2026.07.035_b0530","doi-asserted-by":"crossref","unstructured":"Mazumder S, Higgins PJ, Samarakoon R: Downstream Targets of VHL\/HIF-\u03b1 Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance. 2023, 15(4):1316.","DOI":"10.3390\/cancers15041316"},{"key":"10.1016\/j.jare.2026.07.035_b0535","article-title":"The Distinct Role of HIF-1\u03b1 and HIF-2\u03b1 in Hypoxia and Angiogenesis","volume":"14(9):673","author":"Bakleh","year":"2025","journal-title":"Cells"},{"issue":"15","key":"10.1016\/j.jare.2026.07.035_b0540","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1158\/1078-0432.CCR-20-4574","article-title":"Myeloid Cell-associated Resistance to PD-1\/PD-L1 Blockade in Urothelial Cancer Revealed through Bulk and single-cell RNA Sequencing","volume":"27","author":"Wang","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.jare.2026.07.035_b0545","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.ccell.2024.10.016","article-title":"Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade","volume":"42","author":"Hamidi","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jare.2026.07.035_b0550","first-page":"211","article-title":"Androgen Receptor Signalling in Prostate Cancer: Mechanisms of Resistance to Endocrine Therapies","volume":"17","author":"Quistini","year":"2025","journal-title":"Res Rep Urol"},{"issue":"3","key":"10.1016\/j.jare.2026.07.035_b0555","first-page":"412","article-title":"Androgen receptor promotes immune evasion by suppressing cytotoxic T cell function in prostate cancer","volume":"42","author":"Lu","year":"2024","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.jare.2026.07.035_b0560","first-page":"217","article-title":"Updated European Association of Urology guidelines on renal cell carcinoma: immune checkpoint inhibitor-based combinations as standard of care","volume":"85","author":"Albiges","year":"2024","journal-title":"Eur Urol"},{"issue":"19","key":"10.1016\/j.jare.2026.07.035_b0565","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1200\/JCO.19.00538","article-title":"Nivolumab Alone and with Ipilimumab in previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg\/kg Plus Ipilimumab 3 mg\/kg expansion Cohort results","volume":"37","author":"Sharma","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jare.2026.07.035_b0570","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","article-title":"Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of patients in the CheckMate 650 Trial","volume":"38","author":"Sharma","year":"2020","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.jare.2026.07.035_b0575","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jare.2026.07.035_b0580","article-title":"8 Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial","volume":"29(Supplement_1):S17\u2013S18","author":"Atkins","year":"2024","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.jare.2026.07.035_b0585","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jamaoncol.2024.0938","article-title":"Nivolumab\u2009+\u2009Ipilimumab as Immunotherapeutic boost in Metastatic Urothelial Carcinoma: a Nonrandomized Clinical Trial","volume":"10","author":"Grimm","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jare.2026.07.035_b0590","article-title":"Phase I\/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors","volume":"27(13):3620-3629","author":"Curigliano","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.jare.2026.07.035_b0595","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.2174\/1871530321666210310142141","article-title":"The potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer","volume":"21","author":"Mohsenzadegan","year":"2021","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"11","key":"10.1016\/j.jare.2026.07.035_b0600","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1158\/2326-6066.CIR-19-0146","article-title":"PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma","volume":"7","author":"Zelba","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jare.2026.07.035_b0605","doi-asserted-by":"crossref","unstructured":"Choueiri TK, Kuzel TM, Tykodi SS, Verzoni E, Kluger H, Nair S, Perets R, George S, Gurney H, Pachynski RK et al: Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial. ESMO open 2024, 9(12):104073.","DOI":"10.1016\/j.esmoop.2024.104073"},{"issue":"4","key":"10.1016\/j.jare.2026.07.035_b0610","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2217\/fon-2023-0492","article-title":"The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma","volume":"20","author":"Hoffman-Censits","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.jare.2026.07.035_b0615","article-title":"Recent Advancements in Nanomedicine for 'Cold' Tumor Immunotherapy","volume":"13(1):92","author":"Chen","year":"2021","journal-title":"Nano-micro letters"},{"key":"10.1016\/j.jare.2026.07.035_b0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115361","article-title":"mRNA vaccine in gastrointestinal tumors: Immunomodulatory effects and immunotherapy","volume":"166","author":"Zhang","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"10.1016\/j.jare.2026.07.035_b0625","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jare.2026.07.035_b0630","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jare.2026.07.035_b0635","doi-asserted-by":"crossref","unstructured":"Peng N, Chen D, Yang M, Zeng C, Li W: PARP inhibitors for HRR-deficient metastatic castration-resistant prostate cancer: mechanisms and clinical strategies. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2025, 212:107193.","DOI":"10.1016\/j.ejps.2025.107193"},{"key":"10.1016\/j.jare.2026.07.035_b0640","doi-asserted-by":"crossref","unstructured":"Heijden MSvd, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P, Bedke J et al: Nivolumab plus Gemcitabine\u2013Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med 2023, 389(19):1778-1789.","DOI":"10.1056\/NEJMoa2309863"},{"key":"10.1016\/j.jare.2026.07.035_b0645","doi-asserted-by":"crossref","unstructured":"Emanuelli A, Souleyreau W, Chouleur T, Boeckx B, Pobiedonoscew Y, Cooley L, Derieppe MA, Martineau J, Ambrosetti D, Bernhard JC et al: Targeting the IL34-CSF1R axis improves metastatic renal cell carcinoma therapy outcome via immune-vascular crosstalk regulation. iScience 2025, 28(6):112752.","DOI":"10.1016\/j.isci.2025.112752"},{"issue":"3","key":"10.1016\/j.jare.2026.07.035_b0650","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006262","article-title":"Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)","volume":"11","author":"Siddiqui","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jare.2026.07.035_b0655","doi-asserted-by":"crossref","unstructured":"Necchi A, Van der Heijden MS, Trukhin D, Peer A, Gurney H, Alekseev BY, et al: Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307\/KEYNOTE-672 study. BMC Cancer 2024, 23(Suppl 1):1252.","DOI":"10.1186\/s12885-023-10727-3"},{"issue":"6529","key":"10.1016\/j.jare.2026.07.035_b0660","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.jare.2026.07.035_b0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102198","article-title":"Association of Tumor Mutational Burden and Microsatellite Instability with Response and Outcomes in patients with Urothelial Carcinoma Treated with Immune Checkpoint Inhibitor","volume":"22","author":"Bakaloudi","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.jare.2026.07.035_b0670","doi-asserted-by":"crossref","unstructured":"Saliby RM, Saad E, Kashima S, Schoenfeld DA, Braun DA: Update on Biomarkers in Renal Cell Carcinoma. American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting 2024, 44(2):e430734.","DOI":"10.1200\/EDBK_430734"},{"key":"10.1016\/j.jare.2026.07.035_b0675","article-title":"The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary","volume":"19","author":"Seema","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.jare.2026.07.035_b0680","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2024.08.033","article-title":"Tissue-based Biomarkers Steering Clinical Decisions in patients with Urothelial Cancer","volume":"87","author":"Afferi","year":"2025","journal-title":"Eur Urol"},{"issue":"7867","key":"10.1016\/j.jare.2026.07.035_b0685","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.jare.2026.07.035_b0690","article-title":"AI-driven multimodal algorithm predicts immunotherapy and targeted therapy outcomes in clear cell renal cell carcinoma","volume":"6","author":"Stupichev","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jare.2026.07.035_b0695","article-title":"He YR et al: Novel mRNA adjuvant ImmunER enhances prostate cancer tumor-associated antigen mRNA therapy via augmenting T cell activity","volume":"13(1):2373526","author":"Xu","year":"2024","journal-title":"Oncoimmunology"},{"issue":"8054","key":"10.1016\/j.jare.2026.07.035_b0700","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","article-title":"A neoantigen vaccine generates antitumour immunity in renal cell carcinoma","volume":"639","author":"Braun","year":"2025","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jare.2026.07.035_b0705","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41591-024-03324-9","article-title":"Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial","volume":"31","author":"Li","year":"2025","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.jare.2026.07.035_b0710","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.eururo.2024.05.026","article-title":"Integrative drug screening and multiomic characterization of patient-derived bladder cancer organoids reveal novel molecular correlates of gemcitabine response","volume":"86","author":"Merrill","year":"2024","journal-title":"Eur Urol"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123226005801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123226005801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:33:56Z","timestamp":1785468836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123226005801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":142,"alternative-id":["S2090123226005801"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2026.07.035","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor-specific mechanisms and therapeutic strategies for overcoming immunotherapy resistance in advanced urological tumors","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2026.07.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}